dhodh

DHODH-IN-12 is a leflunomide derivative and a weak dihydrorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.

DHODH-IN-14 is an analog of hydroxyfuran pyrimidine A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor IC50 0.49 μM mouse liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.

DHODH-IN-15 is the hydroxyfuran analogue of A771726. DHODH-IN-15 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 11 μM for rat liver DHODH. DHODH-IN-15 can be used for rheumatoid arthritis.

DHODH-IN-4 is a human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) inhibitor. The IC50 values of PfDHODH and HsDHODH are 4 μM and 0.18 μM, respectively. DHODH-IN-4 has antimalarial activity.

DHODH-IN-8 has antimalarial activity. DHODH-IN-8 is an inhibitor of human and Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) with IC50 of 0.13 μM and 47.4 μM, and Kis of 0.016 μM and 5.6 μM, respectively.

DHODH-IN-16 is an effective inhibitor of dihydroorotate dehydrogenase (DHODH, IC50 = 0.396 nM for human).

DHODH-IN-17 is a human DHODH inhibitor with an IC50 of 0.40 μM. DHODH-IN-17 is a 2- anilino nicotinic acid that can be used in the study of acute myeloid leukemia (AML).

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

Atovaquone (Atavaquone) is a hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

Bipenquinate is a potent and selective inhibitor of dihydroorotate dehydrogenase (DHODH) with IC50 of 20 nM, blocking de novo pyrimidine biosynthesis.

CHIKV-IN-2, a chemical compound, exhibits potent inhibitory activity against the enzyme Dihydroorotate Dehydrogenase (DHODH), crucial for pyrimidine synthesis affecting various viruses' replication. It serves as an effective Chikungunya virus (CHIKV) inhibitor, demonstrating significant cellular antiviral activity (EC90=270 nM) and enhanced liver microsomal stability[1].

PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) is an orally active inhibitor of VEGFA mRNA translation and selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydrolactate dehydrogenase (DHODH).

AG-636 is a potent, reversible, and selective DHODH inhibitor with an IC50 of 17 nM and is orally active. It demonstrates strong anticancer effects.

(E/Z)-Ginkgolic Acid C17:2 (Ginkgolic Acid C17:2) is a natural product extracted from Ginkgo biloba that targets human dihydroorotate dehydrogenase (DHODH).

DHODH-IN-1 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 25 nM. DHODH-IN-1 is an inhibitor of the pyrimidine biosynthetic pathway.

DHODH-IN-13 is an inhibitor of DHODH with IC50 of 4.3 μM for rat liver. DHODH-IN-13 can be used in studies about rheumatoid arthritis.

DHODH-IN-11 is a leflunomide derivative and weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.03.

DHODH-IN-3 is an effective inhibitor of human dihydroorotate dehydrogenase (HsDHODH) with IC50 value of 261 nM. DHODH-IN-3 binds to the ubiquinone binding cavity in DHODH with a Kiapp of 32 nM. DHODH-IN-3 has the potential to treat malaria.

DHODH-IN-18 is a human DHODH inhibitor with an IC50 value of 0.2 nM.

RORγt DHODH-IN-2 (compound 1) is a potent dual inhibitor of RORγt and DHODH, useful for studying inflammatory bowel disease (IBD).

Dhodh-in-20 (Compound 133) is a potent inhibitor of DHODH. Among them, DHODH is an iron-containing flavin-dependent enzyme that is present in the inner membrane of human mitochondria. DHODH-IN-20 showed an inhibitory effect on tumor growth. DHODH-IN-20 has the potential to be used in the study of acute myeloid leukemia.

DHODH-IN-21 is an orally active, selective dihydrolactate dehydrogenase (DHODH) inhibitor (IC50: 1.1 nM). DHODH-IN-21 exhibits anticancer effects and can be used to study acute myeloid leukemia (AML).

DHODH-IN-19, a potent inhibitor of DHODH, has demonstrated research potential for cancer and inflammatory diseases.

DHODH-IN-22 is a potent and selective orally active inhibitor of dihydroorotic dehydrogenase (DHODH) with an IC50 of 0.3 nM, suitable for use in acute myeloid leukaemia (AML) studies.